Pays: Arménie
Langue: anglais
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
diclofenac (diclofenac sodium)
KRKA d.d.
M01AB05
diclofenac (diclofenac sodium)
100mg
tablets film-coated prolonged-release
(20/2x10/) in blister
Prescription
Registered
2019-12-12
Summary of product characteristics CONFIDENTIAL Diclofenac 100 mg prolonged-release tablet MODULE 1 VOL: 1; P: 6 / 32 1.3.1 Diclofenac sodium SPC, Labeling and Package Leaflet SmPCPIL086776_5 09.01.2017 – Updated: 15.10.2019 Page 1 of 13 1. NAME OF THE MEDICINAL PRODUCT Naklofen 100 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 100 mg diclofenac sodium. Excipients with known effect: - sucrose: 105 mg/tablet For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. The prolonged-release tablets are round, biconvex, smooth, red-brown coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - inflammatory and degenerative rheumatic diseases: rheumatoid arthritis, ankylosing spondylitis; arthrosis; extra-articular rheumatism. - pain and inflammatory process of on-rheumatic or post-traumatic origin. - symptomatic treatment of primary dysmenorrhea. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Naklofen prolonged-release tablets containing 100 mg diclofenac sodium are mainly intended for long-term treatment. The dosage for the initial and maintenance treatment is one tablet once daily. If a daily dosage of 150 mg diclofenac sodium is required, Naklofen prolonged-release tablets can be combined with a 50 mg Naklofen gastro-resistant tablet or a 50 mg Naklofen suppository. If the symptoms occur mostly during the night or in the morning, Naklofen prolonged-release tablets should be taken preferably in the evening. As a general recommendation, the dose should be adjusted individually. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control (relieve) symptoms (see section 4.4). _Paediatric population_ Naklofen is contraindicated in children and adolescent (see section 4.3). _Patients with kidney impairment_ Naklofen is contraindicated in patients with renal insufficiency (GFR <15 ml / min / 1.73 m 2 ) (see section 4.3) No specific studies h Lire le document complet